MainStreet Bancshares (NASDAQ:MNSB – Get Rating) released its quarterly earnings results on Monday. The company reported $0.95 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.05, MarketWatch Earnings reports. MainStreet Bancshares had a net margin of 30.08% and a return on equity of 16.49%. The business had revenue of $26.83 million for the quarter, compared to analyst estimates of $19.88 million.
MainStreet Bancshares Stock Up 2.3 %
NASDAQ:MNSB opened at $29.00 on Wednesday. The firm’s 50 day simple moving average is $28.01 and its 200 day simple moving average is $25.61. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 1.02. MainStreet Bancshares has a one year low of $20.77 and a one year high of $30.98. The company has a market cap of $215.76 million, a PE ratio of 10.07 and a beta of 0.52.
MainStreet Bancshares Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, February 10th. Investors of record on Friday, February 3rd will be given a dividend of $0.10 per share. The ex-dividend date of this dividend is Thursday, February 2nd. This represents a $0.40 annualized dividend and a yield of 1.38%. MainStreet Bancshares’s dividend payout ratio is presently 13.89%.
Institutional Inflows and Outflows
Analysts Set New Price Targets
Separately, Stephens raised their target price on shares of MainStreet Bancshares from $28.00 to $32.00 in a report on Monday, November 28th.
About MainStreet Bancshares
MainStreet Bancshares, Inc is a holding company, which engages in the provision of banking solutions through MainStreet Bank. It offers products and services such as checking, deposits, loans, credit cards, mortgages, and savings. The company was founded on March 28, 2003 and is headquartered in Fairfax, VA.
- Get a free copy of the StockNews.com research report on MainStreet Bancshares (MNSB)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- Is It Time To Get Aggressive With Defense Stocks?
Receive News & Ratings for MainStreet Bancshares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MainStreet Bancshares and related companies with MarketBeat.com's FREE daily email newsletter.